Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics insider sales stay rule‑compliant while Phase 2 shows ZORYVE® 68% sweat‑chloride reduction in infants, hinting at breakthrough therapy prospects for XLHED.

Arcutis insider sales are routine; the company’s Phase 2 success and regulatory momentum for ZORYVE signal a bright outlook for investors and clinicians.